Abstract:Introduction: The complexity of Inflammatory Bowel Diseases (IBD) presents challenges for the management of these diseases. Predicting treatment outcomes remains difficult, leading to suboptimal outcomes and high costs. Emerging evidence suggests the potential of the gut microbiome in predicting response to biologic treatments. In this prospective study we aimed to predict treatment response to vedolizumab and ustekinumab in 79 IBD patients by integrating clinical data, gut microbiome profiles and fecal metabolites and validating these findings in a replication cohort of 47 IBD patients. Methods: Treatment response was defined as either continuation or discontinuation of the biologic at six months. We performed whole genome metagenomic shotgun sequencing on the baseline fecal samples to detect microbial and functional profiles. Additionally, over 1000 metabolites were captured through untargeted metabolomic profiling. Baseline diversity, dissimilarity and differential abundance analyses compared responder and non-responder groups. The prediction tool CoDaCoRe was used to identify predictive log-ratio biomarkers. We tested our identified ratios in an external cohort and attempted to replicate the microbiome-based signals of previous studies. Finally, we used a neural-network framework to model the relationship between metabolites and microbes, comparing these clusters in responders and non-responders and tested our approach with different definitions of response. Results: We identified seven metabolites to be differentially abundant between responders and non-responders (FDR < 0.05). However, no significant differences in bacterial species and pathways were detected at baseline between responders and non-responders. Our prediction analysis indicated only marginal predictive utility of the gut microbiome and fecal metabolites for treatment response, when compared to a clinical model using fecal calprotectin, disease duration and disease activity, among other factors (AUC only clinical features: 0.71±0.13, AUC microbial and clinical features: 0.73±0.12). The main predictive features of these models were the disease activity and previous anti-TNF use combined with high abundance of Phocaeicola vulgatus, Bacteroides uniformis and Alistipes onderdonkii, and the low abundance of Ruminococcus gnavus and Faecalibacterium prausnitzii. Testing our identified ratio of 10 species in an external cohort of 47 IBD patients reinforced the lack of predictive power of the microbiome. No replication of previously published predictive signals of the microbiome was observed. Additionally, we identified 2 metabolite clusters and 1 microbiome cluster associated with response, and observed that predictors were highly dependent on the definition of response. Conclusion: While previous studies of similar size have shown that microbial features can predict response to either vedolizumab (VedoNet), or vedolizumab, ustekinumab and anti-TNF, our comprehensive study found no significant differences in the gut microbiome at baseline between responders and non-responders among IBD patients treated with ustekinumab or vedolizumab. Microbial features added no predictive power to drug response in our IBD patient cohort or an independent replication cohort. Addition of metabolite features did not improve predictive power. These findings suggest minimal impact of the pre-treatment gut microbiome on treatment outcomes with these medications in IBD patients with long term chronic disease. Generalizability beyond initial study cohorts is limited, leaving predictors for individualized IBD-medication selection unidentified, but based on this work, likely do not lie in the fecal microbiome.

Microfibrillar-associated protein 4 as a predictive biomarker of treatment response in patients with chronic inflammatory diseases initiating biologics: secondary analyses based on the prospective BELIEVE cohort study

Do Specific Acpas or Other Autoantibodies in A Novel Assay Predict Response to Methotrexate Monotherapy in Patients with Early and Dmard-Naive Ra?

P509 Biomarkers of neutrophil activity and extracellular matrix turnover predict long-term response to vedolizumab in patients with Crohn’s disease

P695 Untargeted proteomics analysis of baseline serum samples prior to biologic therapy initiation

Impact of gluten intake on clinical outcomes in patients with chronic inflammatory diseases initiating biologics: Secondary analysis of the prospective multicentre BELIEVE cohort study

Identification of new biomarkers to promote personalised treatment of patients with inflammatory rheumatic disease: protocol for an open cohort study

P634 Predictors of response and course in patients with inflammatory bowel disease treated with biological therapy: The Danish IBD-Biobank project

A pilot study to identify blood-based markers associated with response to treatment with Vedolizumab in patients with Inflammatory Bowel Disease

P852 Metataxonomic and metabolomic profiling to predict response to anti-TNF therapy in Crohn’s Disease

P715 Multiparametric assessment of IBD and SpA-IBD patients to explore disease biomarkers and response predictors

Multimodal Profiling of Peripheral Blood Identifies Proliferating Circulating Effector CD4+ T Cells as Predictors for Response to Integrin α4β7-Blocking Therapy in Inflammatory Bowel Disease

Association of rheumatoid factor, anti-citrullinated protein antibodies and shared epitope with clinical response to initial treatment in patients with early rheumatoid arthritis: data from a randomised controlled trial

Limited predictive value of the gut microbiome and metabolome for response to biological therapy in inflammatory bowel disease

OA02 Longitudinal high throughput proteomics identifies novel proteins associated with inflammation and future response in new-onset, treatment-naïve rheumatoid arthritis

P518 Dietary and non-dietary predictors of treatment response to adalimumab in anti-TNFα-naïve adults with Crohn’s disease

Microfibrillar-associated protein 4 as a potential marker of acute relapse in inflammatory demyelinating diseases of the central nervous system: Pathological and clinical aspects

Association between pre-biologic T2-Biomaker combinations and response to biologics in patients with severe asthma

P1042 Serum N-glycan Biomarkers Predict Patient Response to Biologics for Crohn’s Disease

P544 Low TNF production and low TREM1 expression as negative predictors for remission under adalimumab therapy in Crohn′s Disease patients

Molecular Profiling of Axial Spondyloarthritis Patients Reveals an Association between Innate and Adaptive Cell Populations and Therapeutic Response to Tumor Necrosis Factor Inhibitors

Exploratory analysis of the potential disconnect between objective inflammatory response and clinical response following certolizumab pegol treatment in patients with active axial spondyloarthritis